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Introduction
Francisella tularensis is a Gram-negative intracellular bac-
terium that is the causative agent of tularaemia. It can be
found naturally occurring in the environment, infecting a
variety of mammals including mice, squirrels and rabbits.
Transmission to humans can occur through direct contact
with infected animals, ingestion or inhalation of organ-
isms, or via arthropod bites.1 Because of the severity of
tularaemia, the low infectious dose, and its past use as a
biological agent, F. tularensis has been classified as a Cate-
gory A Select Agent (http://www.cdc.gov).2 The recent
concerns regarding the possible use of these organisms as
a bioterrorism agent has led to a renewed interest in
understanding the biology of infection, pathogenesis, and
the host response to F. tularensis.
Francisella has been classified into several closely related
species. The subspecies primarily associated with human
disease are F. tularensis subsp. tularensis and F. tularensis
subsp. holarctica. The F. tularensis subsp. tularensis, also
referred to as Type A, is found primarily in North Amer-
ica, whereas the F. tularensis subsp. holarctica, also called
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Summary
Francisella tularensis is a Gram-negative intracellular bacterium that is the
causative agent of tularaemia. Concerns regarding its use as a bioterror-
ism agent have led to a renewed interest in the biology of infection, host
response and pathogenesis. A robust T-cell response is critical to confer
protection against F. tularensis. However, characterization of the cellular
immune response has been hindered by the paucity of tools to examine
the anti-Francisella immune response at the molecular level. We set out
to combine recent advances of genomics with solid-phase antigen delivery
coupled with a T-cell functional assay to identify T-cell epitopes. A subset
of clones, encoding serological targets, was selected from an F. tularensis
SchuS4 ordered genomic library and subcloned into a bacterial expression
vector to test the feasibility of this approach. Proteins were expressed and
purified individually employing the BioRobot 3000 in a semi-automated
purification method. The purified proteins were coupled to beads, deliv-
ered to antigen-presenting cells for processing, and screened with Franci-
sella-specific T-cell hybridomas of unknown specificity. We identified
cellular reactivity against the pathogenicity protein IglB, and the chaper-
one proteins GroEL and DnaK. Further analyses using genetic deletions
and synthetic peptides were performed to identify the minimal peptide
epitopes. Priming with the peptide epitopes before infection with F. tular-
ensis LVS increased the frequency of antigen-specific CD4 T cells as
assessed by intracellular interferon-c staining. These results illustrate the
feasibility of screening an arrayed protein library that should be applicable
to a variety of pathogens.
Keywords: epitope discovery; Francisella tularensis; gateway genomic array;
proteomic array; T lymphocyte
Abbreviations: 6· His, 6· histidine tag; APC, antigen-presenting cell; DHFR, dihydrofolate reductase; LVS, live vaccine strain;
ORF, open reading frame; STS, serological target subset; THIO, thioredoxin.
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Type B, can be found throughout Europe, as well as in
North America. Francisella Type A strains in general
cause a more severe illness in humans than the Type B
strains.3 The SchuS4 strain of F. tularensis subsp. tularen-
sis and the F. tularensis subsp. holarctica derivative known
as the Live Vaccine Strain (LVS), which has been attenu-
ated in humans by serial passage through animals, are
two of the best characterized Francisella strains. Although
there are no licensed vaccines for F. tularensis in the Uni-
ted States, the attenuated Type B strain LVS has been
used as a vaccine in Europe and is widely used in experi-
mental animal studies.4–6 Francisella novicida (which has
also been referred as F. tularensis subsp. novicida) is pri-
marily an animal pathogen that does not generally cause
disease in humans.7 Although Francisella exhibits different
levels of virulence in humans that is strain dependent, all
strains retain a high level of virulence in mice.6 Interest-
ingly, genomic studies revealed a high degree of sequence
identity among the various species (> 95%) although
these analyses also revealed a considerable number of
gene duplications, deletions and rearrangements.8,9
The immune response to F. tularensis is of particular
interest given this bacterium’s potential use as a biological
weapon. Mice inoculated with F. tularensis exhibit many
similarities to infected humans and have often been used as
a model for the host immune response to F. tularensis.6,10
As might be expected for an organism that can grow inside
mammalian cells, studies have revealed that T cells are
major contributors to clearance and immunity.5 The viru-
lence of F. tularensis may be partly related to a weak initial
innate response to live Francisella organisms, as well as to
active suppression of T cells, resulting in a compromised
cell-mediated response.11–17 CD4+, CD8+ and T helper type
17 T cells both contribute to clearance and immunity.18–23
In addition, another unusual T-cell subset (i.e. TCR+,
CD4), CD8), NK1.1)) can also contribute to the cellular
response to F. tularensis.24–27 Interestingly, a role for anti-
bodies and B cells has been implicated in protective
immunity, illustrating additional complexity of the
immune response to F. tularensis.28–31 Recent studies have
shed considerable light regarding the immune response to
this organism, when compared with other intracellular
organisms such as Mycobacterium or Listeria, the immune
response is relatively poorly understood.
Characterization of the cell-mediated immune response
to F. tularensis has been hampered by the lack of tools to
examine and measure the immune response at the molec-
ular level. The identification of specific T-cell epitopes
would greatly aid in the ability to measure and character-
ize the host immune response. We have previously devel-
oped a method to identify T-cell epitopes using T-cell
hybridomas combined with antigens coupled to beads
delivered to antigen-presenting cells (APC).32 Using this
approach we were able to identify an immunodominant
epitope of the Tul4 (also referred to as LpnA) lipoprotein
in F. tularensis.33 We set out to extend this approach and
develop methods that could be used to identify T-cell epi-
topes using an arrayed genomic library of F. tularensis
SchuS4. To test this approach, a selected subset of 45
clones was chosen and subcloned into a bacterial expres-
sion vector pBAD-DEST49 using the Gateway system.
The majority of these clones were selected based upon
their previous identification as serological targets of the
immune response against Francisella,34–37 which we could
use to validate their recombinant expression and might
also be expected to include T-cell epitopes. These clones
were then used to express 6· His-tagged proteins that
were purified using a semi-automated procedure (Qiagen
Biorobot 3000), subsequently coupled to beads, and
screened using a panel of T-cell hybridomas generated
against F. tularensis LVS to identify T-cell epitopes. The
results illustrate that this methodology should also be
applicable to large-scale screening of F. tularensis and
would also be generally applicable to other organisms.
Materials and methods
Mice, cell lines and bacteria
All animal experiments were performed in accordance
with guidelines established by the National Institutes of
Health and the University Committee on Animal
Resources at the University of Rochester or the University
of North Carolina. C57BL/6 (H2b) mice were purchased
from the Jackson Laboratory (Bar Harbor, ME). The
T-cell fusion partner BWZ.36/CD8+ was kindly provided
by Dr Nilabh Shastri and maintained as previously
described.38 Francisella tularensis lysates were generated
from Live Vaccine Strain (LVS) obtained from the CDC
(Atlanta, GA) and SchuS4 from BEI Resources (Manassas,
VA). The F. novicida U112 and the F. novicida U112
transposon mutant library were gifts from Dr Colin Man-
oil.39 Bacteria were grown on chocolate agar and viability
was quantified by serial dilution.
Thioredoxin and dihydrofolate reductase fusion protein
constructs
A genomic library containing the majority of the F. tular-
ensis SchuS4 open reading frames (ORFs) was obtained
from The Venter Institute in an arrayed format of
pDONR221 clones. The 45 thioredoxin (THIO) fusion
proteins from the Serologic Target Subset (STS) array
were produced by shuttling the selected F. tularensis gene
from the pDONR221 entry vector (J. Craig Venter Insti-
tute, San Diego, CA) into the bacterial expression vector
pBAD-DEST49 using the Gateway Cloning technology
(Invitrogen, Carlsbad, CA) following the manufacturer’s
protocol. The expression vector pBAD-DEST49 creates a
fusion protein containing the bacterial protein THIO
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fused in frame with an individual ORF from F. tularensis
SchuS4 followed by V5 and 6· histidine (6· His) coding
regions. Subgenomic constructs used for mapping experi-
ments were generated by PCR amplification from the
appropriate pDONR221 entry clone DNA. Immunoglobu-
lin lB deletion constructs were generated with a 30 primer
that began at the first base pair of the start methionine
codon and a set of 50 primers to amplify gene regions
corresponding to 1–1170, 1–1341, 1–957, 1–666, 1–585
and 1–315 bp. Additional IglB deletion constructs were
generated by the primer sets corresponding to: 1158–
1299, 1278–1413 and 1362–1542 bp. In a similar fashion,
gene regions in GroEL were produced: 1080–1323, 1227–
1476 and 1440–1542 bp; as well as gene regions in DnaK:
1–303, 270–531, 327–531 and 1–366 bp. The PCR prod-
ucts were then cloned into the pCR8/GW/TOPO vector
using the TOPO cloning kit (Invitrogen) following the
manufacturer’s protocol, generating an entry vector that
can then be shuttled to the pBAD-DEST49 vector using
the Gateway Cloning technology as described above. All
proteins produced from pBAD-DEST49 vector will be
designated THIO-(protein) because they are generated as
fusion proteins with thioredoxin.
All dihydrofolate reductase (DHFR) fusion proteins
were generated using the bacterial expression vector
pQE40, which contains a 6· His followed by the murine
protein DHFR, as described in Valentino et al.33 Briefly,
gene fragments were amplified from F. tularensis LVS
genomic DNA using PCR primers specific for: groEL
1–597, 513–1143 and 1080–1323 bp; or dnaK 1–531, 477–
1002, 945–1515 and 1449–1929 bp. Amplified PCR prod-
ucts were cloned into the pQE40 vector using restriction
sites designed into the primers and standard molecular
techniques. All proteins produced from pQE40 vector will
be designated DHFR-(protein) because they are generated
as fusion proteins with DHFR.
Recombinant protein production
Production of THIO fusion proteins were performed in
Escherichia coli strain TOP10 as described by manufac-
turer’s specifications (Invitrogen). Production of DHFR
fusion proteins were performed in E. coli strain M15 (Qia-
gen, Valencia, CA) as previously described.33 Protein
expression was induced in bacteria containing pBAD-
DEST49 (THIO) and pQE40 (DHFR) using L-arabinose
and isopropyl beta-D-1-thiogalactopyranoside, respec-
tively, with an absorbance at optical density at 600 nm of
06–10. Recombinant proteins were isolated by lysing the
bacterial pellets with 8 M urea (pH 80) and purified over
an Ni-NTA column (Qiagen) in high-throughput fashion
using a BioRobot 3000 (Qiagen) as described in Valentino
and Frelinger.40 Protein was coupled to tosyl-activated
M280 magnetic Dynabeads (Invitrogen) as follows: 1 · 107
beads with 8 lg recombinant fusion protein were mixed
overnight at 37 in 01 M borate buffer, washed three times
with PBS using magnetic separation, and diluted to work-
ing volume in PBS (2 · 105 beads/ml). Coupling the
arrayed STS proteins to beads was carried out as described
above in a 12 ml deep 96-well plate. All deletion proteins
were characterized by SDS–PAGE and either stained with
Coomassie Blue or transferred to Hybond C mixed ester
nitrocellulose membrane (GE Healthcare Life Sciences, Pis-
cataway, NJ) and analysed by Western blotting techniques32
(data not shown), followed by primary antibody anti-THIO
(Invitrogen) (1 : 5000) or anti-V5 (Invitrogen) (1 : 5000),
secondary antibody rabbit anti-mouse IgG conjugated to
horseradish peroxidase (Jackson ImmunoResearch Labs,
West Grove, PA), and detection by ECL+ chemiluminescent
reagent (GE Healthcare Life Sciences).
Generation of Francisella anti-sera and immunoblotting
Anti-sera from C57BL/6 mice that were infected intrader-
mally with 105 colony-forming units of F. tularensis LVS
and boosted intraperitoneally 6 weeks later with a 50%
lethal dose of 100 before harvesting blood was provided
by Dr Mingtao Zeng. The Adeno-Tul4 sera, generously
provided by Dr Steven Dewhurst, was generated by
immunizing C57BL/6 mice by tail vein injection with
106 colony-forming units of adenoviral vector expressing
Tul4 followed by a homologous boost before harvesting
sera. After purification, an aliquot of each protein in the
STS array was blotted onto Hybond C membrane using a
96-well dot blot apparatus following the manufacturer’s
specifications (Bio-Rad, Hercules, CA). The membrane
was blocked with 5% non-fat dry milk in TBS-Tween
before probing with either anti-sera from tularaemic
infection at 1 : 300 dilution, Adeno-Tul4 sera at 1 : 300
dilution, anti-THIO antibody at 1 : 5000 dilution, or
anti-V5 antibody at 1 : 5000 dilution for 2 hr at room
temperature. The membrane was then washed three times
in TBS-Tween before addition of rabbit anti-mouse IgG
conjugated to horseradish peroxidase detection antibody
at a 1 : 5000 dilution for 1 hr at room temperature, fol-
lowed by washing and detection using the ECL+ chemilu-
minescent reagent (GE Healthcare Life Sciences).
Generation of T-cell hybridomas
The T-cell hybridomas were produced as described in Val-
entino et al.33 Briefly, hybridomas were generated by intra-
dermal injection into C57BL/6 mice at the base of the tail
with heat-killed bacteria or 1 · 105 viable F. tularensis
LVS4 and allowing the animals to resolve the infection
before harvesting splenocytes. Following several rounds of
in vitro restimulation, the T-cell blasts were fused with
the BWZ.36/CD8+ fusion partner containing lacZ driven
by the Interleukin-2 promotor element as described
previously.32,38 Fusions were grown in hypoxanthine-
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aminopterin-thymidine selection media until clones could
be evaluated for activity, measured by a b-galactosidase
substrate in 96-well plates as previously described.32
Antigen presentation assays
The antigen presentation assay was adapted from the
T-cell antigen discovery assay.32 Presentation assays were
performed by incubating 1 · 105 hybridomas with
5 · 105 APCs in 200 ll total volume per well in a 96-well
tissue culture plate. The APCs were splenocytes isolated
from naive wild-type C57BL/6 mice. All recombinant pro-
teins isolated from bacterial lysates were conjugated to
tosyl-activated beads as described above and used at
2 · 106 beads per well. Assays were also performed in
200-ll volumes in the presence of the synthesized pep-
tides listed below at 10 lg per peptide per well (SynBio-
Sci, Livermore, CA or RS Synthesis, Louisville, KY) and
Francisella lysates at 20 lg per well. Francisella extracts
were produced by killing F. tularensis LVS, SchuS4, or
F. novicida in 70% ethanol overnight at )20 followed by
pelleting and resuspension in PBS.11 Plate bound anti-
CD3 (clone 500A2) (BD Pharmingen, San Jose, CA) was
also included in each assay (not shown in figures) as a
positive control for hybridoma viability and functionality.
After 18–24 hr incubation at 37, cultures were developed
using the b-galactosidase assay. The hybridomas contain a
reporter gene system in which activated T cells express
b-galactosidase.32,38 For data analysis, activated cells were
enumerated as described previously.33
In silico peptide prediction
The refined regions shown by deletion protein mapping
to contain an epitope were analysed with several peptide
prediction algorithms: Rankpep, http://imed.med.ucm.es/
Tools/rankpep.html; NetMHCII 2.0, http://www.cbs.dtu.
dk/services/NetMHCII-2.0/; and IEDB Analysis Resource
using consensus, arbpython, and smm-align prediction
methods http://tools.immuneepitope.org/analyze/html/
mhc_II_binding.html. The entire amino acid sequences
for IglB, GroEL and DnaK proteins were also retrospec-
tively analysed for peptide binders using the prediction
algorithms listed above, as mentioned in the Discussion.
Synthetic peptides
All synthetic IglB and GroEL peptides were synthesized by
SynBioSci and are as follows: IglB 472–486 (IPGK-
PGWYSCKINVI), IglB 475–489 (KPGWYSCKINVIPHI),
IglB 475–486 (KPGWYSCKINVI), GroEL 441–455 (ALL-
RKAIEAPLRQIV), and GroEL 463–477 (SVVVNQVKAN
QGNYG). The peptide DnaK 109–122 (GKKMAPPQVSA-
EVL) was synthesized by RS Synthesis. The Tul4 86–99
(RLQWQAPEGSKCHD) peptide derived from F. tularen-
sis was also synthesized by SynBioSci.33 Ovalbumin
(OVA) 323–339 (pOVAII) peptide (ISQAVHAAHAEIN-
EAGR) served as an irrelevant peptide negative control
and was synthesized by Macro-Molecular Resources (Uni-
versity of Colorado, Fort Collins, CO).
Analysis of in vivo epitope frequency
Analysis of in vivo immunogenicity was performed on the
whole as described previously.20,33 In brief, cohorts of
C57BL/6 mice were treated with one of the following
three experimental protocols: (i) peptide immunization
followed by sham infection; (ii) sham immunization fol-
lowed by F. tularensis LVS infection; or (iii) peptide
immunization followed by F. tularensis LVS infection.
Mice that received peptide immunization were injected in
the footpad with a mixture of IglB 475–489, GroEL 466–
480 and DnaK 109–122 peptides (35 lg each) emulsified
in complete Freund’s adjuvant (CFA) or PBS in CFA.
Mice that were infected were inoculated with 1 · 105 col-
ony-forming units of F. tularensis LVS intradermally at
the base of the tail. Sham immunization or infection was
performed with PBS at matched anatomical locations. All
mice were rested for 3 weeks following peptide or sham
immunization and harvested 10 days after F. tularensis
LVS or sham infection. Splenocytes from all three treat-
ments were stimulated for 18–24 hr in vitro with 100 lg/
ml ethanol-killed F. tularensis LVS extract (FT Ag), IglB
475–489 peptide, GroEL 466–480 peptide, DnaK 109–122
peptide or an irrelevant MHC class II OVA 323–339 pep-
tide. Brefeldin A was added to the incubations for the last
4 hr. Cells were then washed and surface stained with
anti-CD19 PE-Cy7 (BD Pharmingen; clone 1D3), anti-
CD11c PE-Texas Red (Invitrogen; clone N418), anti-
CD11b APC750 (eBiosciences, San Diego, CA; clone M1/
70), anti-TCRab Alexa488 (Biolegend, San Diego, CA;
clone H57–597), anti-CD3 APC (eBiosciences; clone 145–
2C11) and anti-CD4 PacBlue (Invitrogen, clone; RM4–5).
The cells were fixed and permeablized using eBioscience
reagents and protocols (eBioscience), then stained with
anti-IFN-c phycoerythrin (BD Biosciences, San Jose, CA;
clone XMG1.2) and analysed on a Cyan flow cytometer
(Dako-Cytomation, Colorado Springs, CO). The gating
scheme and analysis were performed essentially as previ-
ously described.33 The scheme was employed to identify
IFN-c production by CD4-positive T cells excluding dou-
blets, B cells, dendritic cells and monocytes. A minimum
of 250 000 cellular events were acquired and TCR-
ab+ CD3+ CD4+ splenocytes were analysed for intracellu-
lar IFN-c using SUMMIT software (Dako-Cytomation,
Colorado Springs, CO). Epitope frequency data were sub-
jected to a one-way analysis of variance (ANOVA) and a
Bonferroni’s multiple comparison post-test. The IFN-c+
CD4+ T cells specific for DnaK, IglB and GroEL were
compared against the OVA negative control sample.
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Results
Generation and validation of the STS array
Forty-five F. tularensis SchuS4 clones of interest were
selected from the entry vector library for inclusion in the
STS array and shuttled to the arabinose inducible pBAD-
DEST49 expression vector, which produces a fusion pro-
tein with the Francisella ORF fused in-frame with the
bacterial protein THIO, as well as V5 and 6· His tags
(Fig. 1a). The selected clones were arrayed in a 96-well
plate (Fig. 1b). We took advantage of the presence of
THIO and the V5 tag, which are present on the expressed
proteins to evaluate protein production and purification
by blotting an aliquot of each purified protein onto nitro-
cellulose and probing with an anti-THIO or an anti-V5
antibody (Fig. 1c,d) as described in the Materials and
methods. These blots illustrate that all of the proteins
were produced, albeit at different levels. We also evalu-
ated the array using antisera that should react to many
Francisella protein(s). We used an anti-Tul4 antiserum
that was generated in mice that were immunized with an
adenoviral vector expressing Tul4 (Adeno-Tul4). This
antiserum served as both a positive and negative control;
it specifically reacted with Tul4 as can be seen in the
strong signal on the spot corresponding to Tul4
(FTT0901), whereas little or no reactivity was seen against
the other expressed Francisella proteins blotted onto the
membrane (Fig. 1e). A replicate dot blot containing
proteins from the same 45 clones was probed with an
antiserum from mice that had recovered from infection
and re-challenge with F. tularensis LVS. As seen in
Fig. 1(f), almost all of the proteins in the STS array were
specifically recognized by convalescent F. tularensis sera
(compare Fig. 1e,f) illustrating that these are serological
targets as a result of Francisella infection.
Identification of IglB-, GroEL- and DnaK-specific
hybridomas
We reasoned that proteins that were also serological
targets might also contain T-cell epitopes based on the
phenomenon of linked recognition, in which T-cell and
B-cell epitopes are found in the same molecule. We there-
fore screened this serologically validated array against a
panel of hybridomas reactive with F. tularensis LVS. For
this study we adapted the T-cell antigen discovery assay,
which we have previously used successfully to identify
epitopes in Tul4.32,33 Screening the STS array was accom-
plished by selecting hybridomas that exhibited reactivity
against both F. tularensis LVS and SchuS4 lysates, because
the hybridomas were made from mice immunized with
LVS, but the array was constructed from the SchuS4
strain. In the panel of 30 hybridomas we screened,
we were able to identify three hybridomas that were also
activated by one of the 45 STS array proteins. Figure 2
illustrates a subset of the screen showing the positive
wells, as well as some representative negative wells. For
these experiments we duplicated the clones such that each
of the 45 clones was replicated within a 96-well plate to
provide enhanced reliability for any positive reactivity
observed. This also allowed us to test the feasibility of
screening in a 96-well format that would be amenable to
a high-throughput screen. The FT14 1A5D6 hybridoma
























































































































Figure 1. Validation of the proteins in the
Serological Target Subset (STS) array. (a) Sche-
matic of a pBAD-DEST49 fusion protein. (b)
Forty-five Francisella tularensis SchuS4 genes of
interest were selected for the STS array. The
grid represents the location within the 96-well
plate of each gene, shown as the FTT designa-
tion. Empty wells were also left available for
in-plate controls. (c–f) Proteins from STS array
were expressed and purified, and an aliquot of
each was blotted onto nitrocellulose using a
dot blot apparatus. Membranes were then
probed with anti-thioredoxin antibody (c),
anti-V5 antibody (d), antisera from Adeno-
Tul4 immunization (e) or with antisera from
mice that had recovered from F. tularensis LVS
infection (f), followed by detection with rabbit
anti-mouse IgG conjugated to horseradish per-
oxidase.
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exhibited low reactivity to the majority of proteins from
the array except for the proteins derived from well C12
and its replicate G12 (Fig. 2a), which correspond to IglB.
In a similar fashion, the FT9 hybridoma showed little
reactivity except for the two replicate wells D2 and H2,
which correspond to protein GroEL (Fig. 2b). Finally, the
hybridoma FT6 2B7 was activated by the replicate wells
D5 and H5, identified as the protein DnaK, while the
other wells had very low to negative reactivity (Fig. 2c).
By replicating the proteins in the top and bottom halves
of the plate, any potential positive will occur as two
reactive wells while the rest of the wells serve as negative
controls, strengthening the putative identification.
Francisella novicida transposon mutants can be used
to independently confirm the identification of
hybridoma reactivity
Recently a transposon (Tn) mutant library was con-
structed and characterized in F. novicida U112.39 This
library was created using transposable elements to dis-
rupt all the non-essential genes in F. novicida U112, and
the resulting insertional mutants were isolated and char-
acterized to generate an ordered library where each gene
is represented by one or two independent Tn mutants.39
Cell lysates made from the Tn mutant clones containing
a genetic disruption in a specific ORF, depending upon
the location of transposon insertion, would be expected
to result in partial or complete loss of expression of the
encoded protein. The lack of expression of the specific
protein in the lysates should in turn result in a loss of
hybridoma reactivity, serving as an independent mecha-
nism for validating hybridoma specificity. We reasoned
that we might be able to use this library if the epitopes
recognized by the hybridomas were conserved between
F. novicida U112 and LVS and that lysates expressed the
protein at sufficient levels to activate the hybridomas.
All three hybridomas were activated by LVS lysates as
expected, but they were also activated by the F. novicida
lysate, indicating that the specific epitopes they recog-
nized were conserved (Fig. 3). Having demonstrated that
the F. novicida U112 lysates were able to activate the hy-
bridomas we took advantage of the F. novicida Tn
mutant library in an effort to verify hybridoma specific-
ity. We found that the FT14 1A5D6 hybridoma could
be activated by Tn mutant lysates (217 and 407) where
the iglC gene was disrupted but where the iglB gene was
intact, whereas the IglB Tn mutant lysates (163 and
773) did not activate the hybridoma, supporting the
finding that IglB is the antigen that this hybridoma rec-
ognizes (Fig. 3a). Similarly, as expected for a GroEL-spe-
cific hybridoma, the FT9 hybridoma showed little
reactivity against GroEL Tn mutant lysates (1526) where
the GroEL protein was disrupted, but was capable of
being activated by Tn mutant lysates (217 and 407)
where the groEL gene was intact (Fig. 3b). The results
with the hybridoma we had identified as being reactive
with DnaK were not as conclusive. Although the DnaK
Tn mutant (775) lysate was lower than the parental
strains, the IglC Tn mutants were also somewhat lower
than the parental strains (Fig. 3c). These data, although
suggesting that the hybridoma reacts with DnaK, were
not as definitive as for the other two hybridomas. None-
theless, the F. novicida Tn mutant experiments provide
an independent method that further supports hybridoma
























































































































































Figure 2. Identification of hybridomas that react with the IglB, GroEL
and DnaK proteins. The FT14 1A5D6 (a), FT9 (b) or FT6 2B7 (c)
T-cell hybridomas were incubated in separate plates with C57BL/6
splenocytes and proteins from the Serologic Target Subset (STS) array
conjugated to tosyl-activated beads. After overnight incubation, a
b-galactosidase assay was carried out to identify activated LacZ+ cells.
For screening experiments, each of the 45 proteins in the STS array
was duplicated in a 96-well plate (one replicated in top half, one repli-
cated in bottom half of plate). Francisella tularensis LVS and SchuS4
lysate controls, no antigen wells, as well as, a selection of 10 negative
wells from the plate are shown for reference against the replicate wells
that are positive for hybridoma activation. This experiment was
conducted twice for all hybridomas with similar results.
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of FT14 1A5D6 for the protein IglB and FT9 for the
protein GroEL.
Identification of an epitope region in IglB using
deletion constructs
The FT14 1A5D6 hybridoma was used in antigen presenta-
tion assays to map the region within IglB that contains a T-
cell epitope recognized by the hybridoma. To do so, a series
of IglB deletion constructs were generated, expressed and
used in antigen presentation assays. Figure 4(a) shows that
the FT14 1A5D6 hybridoma is activated when the entire
IglB protein (1–514) is present, but unable to be activated
by any of the smaller fragments including the fragment
containing the amino acids 1–390 of IglB, indicating that
the epitope was probably within the amino acids 390–514.
To refine our epitope search, fragments of IglB spanning
the region from amino acids 386 to 514 were produced.
When these IglB fragments were screened, we found that
the FT14 1A5D6 hybridoma could be activated by amino
acids 454–514, but no reactivity was seen against amino
acids 386–433 or 426–471, indicating that the epitope rec-
ognized is found within residues 454–514 (Fig. 4b). The
stimulatory 454–514 fragment could be further refined to
omit the 17 amino acids that are shared with the non-stim-
ulatory 426–471 fragment, because if these 17 residues con-
tained an epitope, both fragments would have elicited
hybridoma activation. Hence, these results indicate that
residues 471–514 of IglB contains the epitope recognized
by the FT14 1A5D6 hybridoma.
Identification of epitope regions within GroEL and
DnaK
To map the epitope regions within GroEL and DnaK
recognized by the FT9 and FT6 2B7 hybridomas, respec-
tively, we used the same general approach discussed
above for IglB mapping. As seen in Fig. 4(c), the FT9
hybridoma is not only activated by full-length GroEL
(1–545) but also by the fragment 360–545 and it is not
activated by the other fragments, indicating that the epi-
tope recognized was found within amino acids 360–545
of GroEL. Using fine mapping fragments the reactivity
seen against the 360–545 region was further refined to
residues 409–492, which can be further limited to resi-
dues 441–480 based on reactivity to deletion constructs
(Fig. 4d). As seen in Fig. 4(e), the FT6 2B7 hybridoma
can be activated by full-length DnaK (1–643), as well as,
the fragment containing residues 1–177. Fine mapping
of the 1–177 region showed that fragments 1–122 and
109–177 were capable of activating the hybridoma, indi-
cating that the epitope could be found within the 14
residues shared between these constructs, amino acids
109–122 (Fig. 4f). Hence, we have identified the regions
441–480 of GroEL and 109–122 of DnaK to contain
T-cell epitopes.
Peptide validation of hybridoma specificity
To validate the results of the mapping studies using
recombinant protein we had a set of IglB, GroEL and
DnaK peptides synthesized based upon the fine mapping
data (Fig. 4b–d) and aided by in silico prediction algo-
rithms, as described in the Materials and methods. In all
peptide reactivity assays, hybridoma reactivity was not
seen against irrelevant peptide controls or the no antigen
negative control (Fig. 5). IglB protein mapping data
(Fig. 4a,b), together with the peptide predictions, enabled
us to refine our search to three peptides within the amino
acids 472–489, of which the peptide IglB 475–489 had the
greatest stimulatory capability, and to a lesser degree the
peptides containing residues 472–486 and 475–486 of IglB

































































































Figure 3. Genetic evidence for hybridoma specificity. FT14 1A5D6
hybridoma (a), FT9 hybridoma (b), or FT6 2B7 hybridoma (c) were
incubated with splenocytes from C57BL/6 mice and lysates from
Francisella tularensis LVS (LVS Ag), F. novicida U112 (Novicida Ag)
or F. novicida U112 transposon mutant clones (indicated with Tn).
After overnight incubation, a b-galactosidase assay was conducted to
identify and enumerate activated cells. These experiments have been
conducted two or more times with similar results, quadruplicate
wells per treatment were counted and the average activated cells per
well are shown.
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1A5D6 hybridoma derived from a mouse following live
infection recognizes an epitope within the amino acids
472–489 of IglB, with residues 475–489 being capable of
maximal activation. GroEL protein mapping data
(Fig. 4c,d) together with the in silico MHC-binding pre-
diction identified two peptides as putative epitopes. These
peptides were screened for reactivity against the FT9
hybridoma and we found that only the peptide containing
residues 466–480 of GroEL was able to activate the
hybridoma, identifying this peptide as the epitope
recognized (Fig. 5b). In a similar fashion, the DnaK map-
ping data (Fig. 4e,f) strongly indicated that the epitope
recognized by the FT6 2B7 hybridoma was contained
within residues 109–122. As expected, the peptide DnaK
109–122 was capable of activating the FT6 2B7 hybrid-
oma, indicating that it is indeed the epitope recognized
(Fig. 5c).
Assessment of IglB 475–489, GroEL 466–480 and
DnaK 109–122 epitope frequency in vivo
By using T-cell hybridomas stimulated by an infection, the
epitopes identified are inherently validated as being natural
T-cell epitopes. However, this approach does not address
whether or not the epitope is dominant within the response
or a comparatively rare event, perhaps recognized by rela-
tively few T cells. To determine the frequency of T cells that
recognize the IglB, GroEL and DnaK epitopes, we examined
the F. tularensis response using intracellular IFN-c in CD4+
T cells from mice acutely infected with Francisella, mice
immunized with a mixture of IglB, GroEL and DnaK pep-
tide epitopes and rested, or from mice primed with the
mixture of peptide epitopes and challenged with F. tularen-
sis LVS. Spleen cells were stimulated ex vivo with F. tularen-
sis lysates (FT Ag) or with the individual peptides and were
stained with an array of cellular markers followed by multi-
colour flow cytometry to identify activated IFN-c+ CD4+
T cells and exclude B cells, dendritic cells and monocyte
populations from the analysis. As shown in Fig. 6(a),
40 days after immunization, the CD4+ splenocytes from
mice that were immunized with only peptide mixture after
this extended rest failed to produce IFN-c when stimulated
with FT Ag or any peptides directly ex vivo. Splenocytes
from mice that had been acutely infected with F. tularensis
LVS and isolated at the height of the primary response pro-
duced IFN-c when stimulated with Francisella extracts (FT
Ag) as expected, however, the DnaK, IglB and GroEL pep-
tides did not stimulate a detectable number of CD4+ T cells
to produce IFN-c, with the exception of one out of the
three mice generating splenocytes that were stimulated by
the GroEL 466–480 peptide (Fig. 6b). It was of particular
interest to determine whether immunization with the iden-
tified peptides could augment the frequency with which
each epitope is recognized during a live F. tularensis infec-
tion. Mice were primed with the peptide mixture immuni-
zation followed by F. tularensis LVS infection 3 weeks later.
Splenocytes from these mice were harvested 10 days after
infection, stimulated, and analysed as described above. As
expected, CD4+ splenocytes from these mice also produced
IFN-c when stimulated with FT Ag and the total frequency
of CD4+ IFN-c+ cells was similar to that seen in mice from
infection alone (Fig. 6c). Interestingly, when the mice were
inoculated with F. tularensis LVS following a peptide
prime, the frequency of IglB epitope-specific T cells recog-
nized was significantly increased (P < 005) compared with
the frequency seen in infection alone, while DnaK-specific
T cells were increased but failed to reach statistical signifi-
cance (Fig. 6c). These results suggest that the epitopes arise




























































































































Figure 4. Fine mapping hybridoma specificity using fusion proteins
made from deletion constructs. Hybridomas were incubated with
C57BL/6 splenocytes and proteins were conjugated to tosyl-activated
beads. No antigen wells, THIO-IglC, or DHFR-OVA were included
as negative controls. The FT14 1A5D6 hybridoma was used for
screening IglB deletion proteins (a) and fine mapping experiments
(b). The FT9 hybridoma was used for screening GroEL fragments (c)
and fine mapping experiments (d). The FT6 2B7 hybridoma was
used for screening DnaK fragments (e) and fine mapping experi-
ments (f). After overnight incubation, a b-galactosidase assay was
carried out to identify and enumerate activated cells. Quadruplicate
wells per protein were counted and the average activated cells per
well were presented as representative data from two experiments for
each hybridoma.
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recognized after peptide priming in the context of a sec-
ondary challenge. Reactivity to the peptide immunization
could not account for these findings because mice immu-
nized with a peptide mixture alone did not result in much
residual T-cell reactivity (Fig. 6a).
Discussion
We set out to develop a method to identify T-cell epi-
topes using a combination of genomics and a functional
screen for T-cell activation employing a solid-phase anti-
gen delivery system. Previously, we have used a variation
of this approach to identify epitopes in single target pro-
teins.32,33 In the current study, we took advantage of the
availability of a library of F. tularensis SchuS4 ORFs con-
structed in a Gateway entry vector to develop a method-
ology that could be scaled to a large number of clones.
To test the feasibility of this approach for high-through-
put screening using the Gateway cloning system, a subset
of 45 clones from the arrayed library of entry clones,
termed the STS array, was shifted into the bacterial
expression vector pBAD-DEST49. This expression vector
also encodes a 6· His tag allowing for the expressed
proteins to be isolated in a semi-automated procedure
using Ni-NTA columns.40 The purified proteins could
then be coupled to beads to deliver antigens to APC in a
modified T-cell antigen discovery assay, previously used
in our laboratory.32,33 This solid-phase antigen delivery
system is an extremely efficient means by which to deliver
antigen to APC41–43 and because these APC process and
present the antigen, they can be used in a functional
screen with T-cell hybridomas. The majority of the 45
STS array clones were chosen because previous works
showed that they were targets of an antibody response to
Francisella.34–37 By choosing proteins that were serological
targets, we were able to independently validate their
expression using serum from F. tularensis LVS-infected
and -challenged animals (see Fig. 1). Furthermore,
because the STS proteins are targets for antibodies, this
indicates that Francisella expressed these proteins in the
host. We also reasoned that molecules that contained B-
cell epitopes might also contain T-cell epitopes because of
linked recognition and indeed we were able to identify T-
cell antigens using this approach. Although a more com-
prehensive analysis is needed to determine if the STS pro-
teins are enriched in T-cell epitopes, it is interesting that
the reactivity of three out of 30 hybridomas could be
identified with this approach. Recently this concept of
linked recognition in complex pathogens received experi-
mental support from a study finding that vaccinia virus
antigen that contained CD4+ T-cell epitopes was also




















































































































































































































































































Figure 5. Epitope mapping using peptides. Hybridomas were incubated with C57BL/6 splenocytes without antigen or with irrelevant peptide con-
trols Tul4 86–99 or pOVAII peptide. (a) FT14 1 A5D6 hybridomas were also incubated with IglB 475–489, IglB 472–486, or IglB 475–486 pep-
tides. (b) FT9 hybridomas were also incubated with GroEL 444–458, or GroEL 466–480 peptides. (c) FT6 2B7 hybridomas were incubated with
DnaK 109–122 peptide. After overnight incubation, a b-galactosidase assay was performed to identify activated cells. Four replicates per treatment
were done per experiment, a repeat of two experiments is shown. Average number of activated cells per well and standard deviation from a rep-
resentative experiment have been shown. Asterisk denotes which were plotted away from the axis, because of extremely low reactivity in the par-
ticular wells, for clarity.
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The three molecules we identified in the initial screen
as containing T-cell epitopes were also confirmed by a
genetic approach that took advantage of an arrayed Tn
mutant library of F. novicida.39 This library has been use-
ful for a variety of studies including the identification of
virulence determinants.45,46 Here we have used the Tn
mutants as a source of protein knockout lysate, with the
rationale that cellular extracts made from the Tn mutant
clones should be deficient in the molecule encoded by the
transposon disrupted gene and so would test if the T-cell
hybridoma recognized this antigen. The availability of the
arrayed library of Tn mutants provided a straightforward
means of independently confirming this approach,
although it should be noted that there are several poten-
tial caveats to this strategy. For example, as the library
used in the current study was made in a different species
of Francisella, it was important to confirm that the T-cell
hybridomas could recognize the F. novicida antigen. Our
experiments found that the hybridomas were in fact
cross-reactive for the three molecules, probably because of
the high degree of genetic similarity and protein homol-
ogy between the strains of Francisella.8 Indeed, the
sequences of all three epitopes we identified are identical
in F. tularensis SchuS4, F. tularensis LVS and F. novicida.
Additionally, it should be noted that the Tn mutants
might potentially express a fragment of the disrupted pro-
tein, which could still activate the hybridoma, or that a
mutation in one gene might affect the expression of other
gene products. Nevertheless, despite these potential con-
cerns, we found that two out of the three proteins exam-
ined using this approach confirmed our initial
assignment; whereas in the case of DnaK these analyses
gave a suggestive, but not definitive, answer (see Fig. 3).
A retrospective analysis of the epitope location compared
with Tn insertion provides a potential explanation for this
finding. The identified epitope in DnaK is located
upstream from the insertion of the transposable element,
which might result in potential protein fragments con-
taining the recognized epitope and hybridoma reactivity.
The ultimate validation and identification of the epitopes
was also supported using analyses of protein fragments
and the chemical synthesis of the peptide combined with
biological functionality testing.
Here we report that using the approach described above
we have been able to identify epitopes in the proteins GroEL,
DnaK and IglB. It is interesting that two of the epitopes we
identified are in the chaperone proteins DnaK and GroEL.
These were previously identified as strong serological tar-
gets37,47 and in our analyses these also showed strong anti-
body reactivity in serum that had been primed and
challenged with live F. tularensis LVS (see Fig. 1f). Indeed,
an extensive analysis of primary immunization strategies
examining the humoral response resulting from live infec-
tion or from immunization with killed F. tularensis LVS ad-
juvanted with ISCOMS, CpG or ALUM strategies listed
GroEL as the number one target of antibody reactivity,
whereas DnaK was listed as number 21.37 Additionally, a
long-lasting CD4 and CD8 T-cell recall response to F. tular-
ensis heat-shock proteins, including DnaK and GroEL, has
been shown in humans48 and a significant cell-mediated
response was seen against GroEL in mice although the epi-
topes were not identified.49 Interestingly, F. tularensis
GroEL was recently shown to have adjuvant-like activity that
synergized with lipopolysaccharide from Francisella to
activate human macrophages.50 It is intriguing that chaper-
one proteins have been suggested to have adjuvant activity
















































































Figure 6. Assessment of epitope frequency in vivo. Splenocytes were
harvested from mice that were either immunized with a peptide mix-
ture only (a), sham immunized and challenged with Francisella tular-
ensis LVS (b), or immunized with a peptide mixture and challenged
with F. tularensis LVS. (c) Splenocytes were stimulated briefly with
lysate from F. tularensis LVS (FT Ag) as a positive control and vari-
ous peptides; DnaK 109–122, IglB 475–489, and GroEL 466–480.
OVA 323–339 peptide was included as a negative control. Brefeldin
was introduced for the last 4 hr of culture. Splenocytes were then
stained with fluorescent antibodies, as described in the Materials and
methods, and analysed for CD4+ IFN-c+ cells using FACS. Symbols
represent stimulation data from individual mice within the different
immunization groups and are graphed as CD4+ IFN-c+ double-posi-
tive cells per 106 splenocytes. Asterisk, P < 005; ns, not significant.
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tially impact an immune response.51–53 Finally, from an
immunological standpoint they are also interesting targets
because they are evolutionarily conserved and a response
directed to a chaperone protein has the possibility to be
cross-reactive with several other bacterial species.
The identification of a T-cell epitope in IglB is interest-
ing in that it is, to our knowledge, the first direct valida-
tion of a molecular epitope in a Francisella pathogenicity
island (FPI) protein. After entry into macrophages or den-
dritic cells, FPI proteins are crucial for the ability of Fran-
cisella to escape the phagolysosomal compartment and the
capability for replication within the host cytosol.54–56
Indeed, recent studies using iglB mutants show impaired
intracellular replication and phagosomal escape, resulting
in an attenuated infection in mice and Drosophila melanog-
aster models, implicating IglB as a crucial factor for viru-
lence and pathogenicity.46,57–60 Intriguingly, IglB was
recently shown to be one of the earliest of the FPI proteins
up-regulated when Francisella is within macrophages.61
Furthermore, other studies have shown that IglB interacts
with other pathogenicity island proteins either directly, for
example with the protein IglA, or complexed with proteins
such as IglC and PdpD.62–64 The proteins IglA and IglB
share homology with proteins of the newly defined Type
VI secretion system (T6SS), a system identified in nearly
100 Gram-negative bacteria species.64–66 A recent study by
Barker et al.67 has provided additional evidence supporting
the homology of the FPI to T6SS and has also identified
secreted effectors, VrgG (FTT1347) and IglI (FTT1352),
providing evidence that FPI genes may be components of a
secretory system. As speculated in Broms et al., IglB may
be part of a T6SS apparatus that associates with IglA to
secrete the effector molecules, for example IglC, a crucial
virulence factor,58,68 into the host cell to modulate phagos-
omal escape and allow infective propagation.62
Interestingly, our immunization data (see Fig. 6) would
suggest that the epitopes identified might be considered
subdominant or cryptic in the context of a live infection.69–
71 Although there appeared to be a response to GroEL in a
primary response to live LVS infection in one animal, over-
all, T cells recognizing these epitopes were only present at
relatively low frequency in the primary immune response
infection, when compared with the epitope frequency seen
against the lipoprotein Tul4 we reported previously.33
However, after immunization with a mixture of the peptide
epitopes we identified, T-cell responses to IglB, and to a les-
ser degree DnaK, could be recalled by a live infection (see
Fig. 6). Of the newly identified epitopes, the IglB epitope
shows the greatest amount of reactivity. Whether or not
this is the result of a characteristic of IglB expression, such
as protein level, or when it is expressed during infection
remains to be determined. It is particularly intriguing that
IglB can be recognized because FPI proteins are potentially
good candidates for vaccines. As mentioned above, deletion
of FPI proteins often results in decreased virulence54,56,68 so
it would not be easy for bacteria to evade an immune
response by deleting the target antigen. A recent study
showed that immunization with live recombinant Listeria
expressing IglC provided protection against a live aerosol
challenge of F. tularensis SchuS4, although the epitopes
were not identified by that study.72 The identification of
epitopes, including the IglB epitope described here, should
aid in the investigation of various vaccine strategies includ-
ing ones that might target FPI proteins, as it is likely an
effective vaccine would need to target multiple epitopes
and also stimulate humoral immunity.28,73,74
Whether any of the epitopes we identified are protective
remains to be determined. The protein sequences encoding
these epitopes are conserved across the F. tularensis
SchuS4, F. tularensis LVS, and F. novicida strains, which is
interesting to consider in light of the protection provided
by these different strains with infection. The F. tularensis
LVS strain has been shown to provide partial protection
against F. tularensis SchuS4, suggesting that shared epi-
topes could be involved in protection.7 On the other hand,
Cong et al.57 using an iglB gene-deleted F. novicida strain
showed only limited protection against F. tularensis
SchuS4. This might suggest that private epitopes unique to
F. tularensis SchuS4 are needed to provide optimal protec-
tion. However, it is also important to consider that differ-
ences in the biology of the different strains of Francisella,
such as the nature of the innate response to infection,
might also play important roles in their immunogenicity,
as well as pathogenicity. While the nature of protective T-
cell responses to Francisella is relatively poorly understood,
the identification of epitopes will nevertheless greatly aid
in elucidating the kinetics and magnitude of T-cell
responses to this organism. Further studies will be required
to determine which epitopes are protective.
There are a variety of methods to identify epitopes.75–86
By using a functional screen using T cells to identify epi-
topes, the method used here immediately validates that
they are authentic T-cell epitopes. Further, because this
approach does not make any a priori assumptions, one can
identify epitopes that are not easily predicted by MHC-
binding algorithms. Indeed, we analysed the IglB, GroEL
and DnaK proteins retrospectively using several epitope-
predicting website algorithms (IEDB: Arbpython and
SMM-align; Rankpep; and NetMHCII 2.0: NN-Align), and
found that the different algorithms gave dramatically dif-
ferent predictions for peptide epitope characteristics, such
as, the total number of epitopes, core sequence and bind-
ing affinity.87 Moreover, we found that no one algorithm
entirely predicted the epitopes we identified using the
functional screen. For example the IglB epitope, which was
the strongest epitope to be recalled by live infection, was
successfully predicted by the Rankpep algorithm only (pre-
dicted binding threshold > 952), whereas all other binding
algorithms indicated that the peptide would be a weak
binder at best (binding affinity IC50 > 5000 nM). Neverthe-
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less, we would emphasize that the use of immunoinformat-
ics tools and the unbiased functional screens we have
employed are complementary methods. Indeed, we rou-
tinely take a combinatorial approach, having found that
once we have mapped T-cell reactivity to a relatively small
region using the deletion protein technique, the algorithms
are extremely helpful in designing peptides to test. The
approach employed in the current study, in which the anti-
gen is first expressed and purified, and subsequently deliv-
ered to APC for processing and presentation, has features
that make it particularly attractive and versatile in several
contexts. For example, once the proteins are expressed and
purified they not only can be used in an arrayed format to
characterize antibody responses,37 but also used as immu-
nogens themselves. We have used this approach to charac-
terize T-cell epitopes in F. tularensis previously for Tul433
and more recently applied this approach to IglC (data not
shown). Importantly, once the proteins are expressed and
purified, they can be used to identify epitopes in different
mouse strains with varying MHC haplotypes. This
approach should also be applicable to HLA transgenic
mice, which can be used to model human immune
responses because the proteins are delivered to APC for
processing rather than using panels of peptides designed to
bind specific MHC molecules.88 Finally, this approach is
scalable to thousands of clones. The methods we have pre-
sented here, and ever increasing availability of genomic
resources, will ultimately make this approach feasible for
characterizing immune responses to a variety of organisms.
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